STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests

The savings got promised in public. The deals got cut in private. Guess which number wins.

The projected savings from Trump's "most-favored nation" pricing policy might be drastically reduced by secretive deals with pharma companies, a new analysis finds.